



Local 513 - Fringe Benefit Funds

International Union of Operating Engineers, AFL-CIO

3449 Hollenberg Drive
Suite 150
Bridgeton, MO 63044
(314) 739-2973
Fax (314) 739-8059
(800) 511-0101

© 72

Labor Trustees
Pat Kammer
David Hofmann
Lealon Vaughn

Management Trustees
Jay Schultehenrich
Mike Mooney
Charlie Goodwin

Date: May 2, 2016
To: All Active and Retiree Plan Members
Welfare Fund of Engineers Local 513
From: The Board of Trustees
Re: Prior Authorization on Specialty Drugs Effective July 1, 2016

Effective July 1, 2016, there will be a prior authorization (PA) requirement on specialty drugs. A PA is documentation of the appropriateness of the prescribed medication for the diagnosis. This procedure helps manage the use of medications identified as high-dollar, high-risk, or having the potential for inappropriate use. On or after July 1, 2016, if you are prescribed a specialty medication, your prescribing physician will need to submit a prior authorization request to MedImpact in order to receive the medication. Please note that if you are already being prescribed a specialty drug, you will not be required to submit a PA for that prescription or any subsequent refills. This plan change only applies to new prescriptions after the effective date.

You can initiate the PA process by contacting MedImpact at 1-800-788-2949 or providing the attached Medication Request Form to your physician. If you do not initiate the PA, you will be notified about the PA requirement at the pharmacy, which may be able to initiate the PA for you. Note, however, that the pharmacy will not be able to fill your prescription for a specialty drug until the PA process has been completed and your prescription is approved.

The following classes and drugs are examples of specialty drugs that would require PA:

Arthritis/Psoriasis Drugs: Enbrel, Humira, Orencia, Otezla, Simponi, Stelara, Xeljanz

Growth Hormones: Genotropin, Norditropin, Nutropin, Omnitrope, Tev-tropin

Hepatitis C: Daklinza, Harvoni, Olysio, Sovaldi, Technivie

Multiple Sclerosis: Aubagio, Avonex, Betaseron, Copaxone, Gilenya, Rebif, Tecfidera

Oncology: Afinitor, Farydak, Gleevec, Jakafi, Nexavar, Sprycel, Sutent, Tarceva, Xalkori, Zelboraf

Pulmonary Arterial Hypertension: Adcirca, Adempas, Letairis, Revatio, Opsumit, Tracleer

Pulmonary Fibrosis: Esbriet, Ofev

Note that the drugs listed above are not all inclusive.

This notice should be kept with your Summary Plan Description.

Should you have any questions about your prescription drug benefits, please call the Fund Office at (314) 739-2973.